Division of Hematology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
Curr Opin Hematol. 2020 Mar;27(2):76-80. doi: 10.1097/MOH.0000000000000560.
Since its approval in November 2018, venetoclax with a hypomethylating agent backbone has shown promising efficacy for older, newly diagnosed acute myeloid leukemia (AML) patients who are unfit for standard intensive induction chemotherapy. This regimen is well tolerated, allows for deep and durable responses and may be increasing the prevalence of the disease. Although there is justifiable excitement, it remains to be seen to what extent venetoclax-based regimens, as they are currently administered, will have a long-term impact on the treatment of AML. This review aims to evaluate the strengths of the regimen that deserve enthusiasm as well as its shortcomings, which should be viewed as opportunities for improvement.
The clinical efficacy as well as the novel mechanism of venetoclax with hypomethylating agents will be described here.
Venetoclax with hypomethylating agents do not represent the holy grail for AML, but this regimen is a promising step in the right direction, and proof of principle that a low-intensity therapy can have a major impact on this disease.
目的综述：自 2018 年 11 月获批以来，维奈托克联合低甲基化剂方案已显示出对不适合标准强化诱导化疗的老年新诊断急性髓系白血病（AML）患者有较好的疗效。该方案耐受性良好，能产生深度和持久的缓解，并可能增加该疾病的患病率。尽管有合理的兴奋，但尚不清楚目前所采用的维奈托克方案在多大程度上会对 AML 的治疗产生长期影响。本综述旨在评估该方案值得令人兴奋的优势以及其应被视为改进机会的缺点。
最近发现：本文将描述维奈托克联合低甲基化剂的临床疗效及新机制。
总结：维奈托克联合低甲基化剂方案并不代表 AML 的圣杯，但该方案是朝着正确方向迈出的有希望的一步，证明低强度治疗可对该疾病产生重大影响。
